Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid tumors. Anti-CD47 therapies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer.

Arch Oncology has developed a functionally diverse antibody platform and is advancing a novel anti-CD47 antibody to the clinic that not only acts as an immune checkpoint inhibitor, but also selectively kills tumor cells (non ADCC).